Immunomodulators market size is expected to reach USD 233.7 billion by 2025

The market is anticipated to be predominantly driven by high R&D investments employed by the prominent companies, resulting into the large-scale production of new and therapeutically advanced drugs. This is believed to widen the influx of drugs at an unprecedented rate into the immunomodulators market hence providing highly efficacious treatment alternatives for numerous autoimmune and inflammatory diseases.

In addition, increasing drugs resistance is predicted to be responsible for boosting the clinical urgency to develop potentially new generation immunomodulators with targeted therapy mechanisms. The aforementioned factors cumulatively are expected to present significant growth opportunities over the forecast period.

Furthermore, burgeoning presence of the key players is expected to promote the awareness levels pertaining to benefits of immunomodulators amongst the patients as well as the physicians. This is further expected to widen the immunomodulators industry growth potential during the forecast period.

In addition, increasing adoption of monoclonal antibodies for a wide range of indications, such as, multiple sclerosis, Crohn’s disease, rheumatoid arthritis, and Non-Hodgkin’s Lymphoma, which is expected to boost immunomodulators industry over the forecast period. The consistent number of product approvals of highly significant monoclonal antibodies in autoimmune diseases is predicted to be responsible for widening the scope of growth.

View summary of this report, Click Here 

Further Key Findings From the Study Suggest:

• Immunosuppressant held the largest share of the product segment in 2015, owing to increasing number of transplantation procedures and need to prevent organ rejection
• Antibodies held the dominant share of immunosuppressant in 2015, owing to extensive utilization in kidney, liver, heart, and lung transplants resulting in greater revenue generation
• Immunostimulants expected to grow lucratively as a result of lower influx of immunostimulant generics for application in HIV, cancer and multiple sclerosis
• In 2015, North America dominated the global immunomodulators market owing to presence of wide number of established pharmaceutical companies involved in extensive commercialization
• The prominent participants are undertaking research and clinical collaborative strategies to yield new drugs and thereby to gain competitive advantage
• For instance, in March 2015, Novartis AG entered into research collaboration with Aduro Biotech. This was carried out to enhance its next generation cancer immunotherapy product pipeline

Click Here For Access Full Report : https://goo.gl/rBVh2n

Drug And Gene Delivery Systems Market Is Expected To Reach USD 786.9 Billion By 2025

Rising investment by the market players to develop innovative drug delivery systems to cater to the demand by the patients as well as to increase the bioavailability at minimum quantity of active pharmaceutical ingredient is driving the market growth. Additionally, increasing focus on R&D of gene delivery systems owing to the high growth potential of gene therapy for the treatment of a wide range of diseases is expected to fuel the market growth in the future.

Drug delivery systems are in a constant evolution along with the changing preference by the patient. For instance, initially, hormone replacement therapy was widely prescribed in the form of pills, whereas, it is now available in the form of prefilled syringes, patches, vaginal rings, gel, and sprays. The principal purpose of development of different forms of delivery systems is to increase the ease of use. Factors such as aesthetics of the delivery systems, price, and amount of API are also considered while designing the drug delivery system.

                             View summary of this report, Click Here 

Further key findings from the study suggest:

• The market study suggests that oral segment dominated the market in 2015
• The convenience of use and low manufacturing cost are the prime factors responsible for the dominance of the oral delivery segment
• Injectable segment is expected to show a lucrative growth rate owing to the introduction of technically advanced injecting devices that enable convenient self-injection
• North America dominated the market in 2015 and is expected to remain dominant throughout the forecast period owing to highly developed healthcare infrastructure and high healthcare spending
• Asia pacific is expected to exhibit the fastest growth rate during the forecast period owing to the factors such as rapidly developing economies, growing disposable income, and high adaption of the advanced delivery systems
• A few of the major market players in drug delivery systems space are F. Hoffmann-La Roche Ltd, Pfizer, Inc., Johnson and Johnson private Ltd, Novartis AG, Becton, Dickinson and Company, and Bayer AG.
• Major market players in the gene delivery systems space are SiBiono GeneTech Co., Unique N.V., Epeius Biotechnologies Corporation, Human Stem Cells Institute, and Shanghai Sunway Biotech Co., Ltd.

Click Here For Access Full Report : https://goo.gl/jK3VdW

Surgical Equipment Market Size Anticipate To Reach USD 20.3 Billion By 2025

The global surgical equipment market is anticipated to reach a value of USD 20.3 billion by 2025, according to a new report by Grand View Research, Inc. The rapidly escalating number of minimally invasive surgical procedures throughout the world is expected to support market growth.

Chronic diseases are one of the major leading causes of surgeries at a global level. Increasing prevalence of chronic diseases, such as neurological and cardiovascular disorders, is affecting the society to a great extent. As a result of which, the number of surgeries is increasing. This is mainly due to the fact that surgery is the primary treatment for people suffering from such disorders. In addition, minimally invasive surgeries are also trending as treatment for heart diseases.

Road and other accidents are also expected to drive the surgical instruments market over the forecast period. This is due to the fact that accidents might lead to severe injuries. As a result of which, wound closure surgeries are anticipated to rise, thereby, supporting the demand for surgical equipment.

                             View summary of this report, Click Here 

Further key findings from the study suggest:

• Surgical sutures and staplers dominated the surgical equipment market in 2015 due to its high cost and greater usage in wound closure treatments
• Electrosurgical equipment are expected to show lucrative CAGR over the forecast period owing to increasing adoption of minimally invasive surgeries
• Obstetrics and gynecology held the largest market share in 2015, owing to growing number of caesarean surgeries worldwide
• Plastic Surgery Statistics Report data showcased 1.7 million cosmetic surgical procedures in 2015 and a 2% rise from the 2014 data. This infers a significant rise in plastic and reconstructive surgeries in the coming years
• North America contributed toward the largest revenue in 2015 owing to well-established infrastructure and technologically advanced instruments for surgeries
• Asia Pacific is projected to witness an attractive CAGR over the forecast period, primarily due to increasing prevalence of chronic cardiovascular diseases
• Few key players for the market include B. Braun Melsungen Ag; Smith & Nephew plc; Zimmer Biomet Holdings, Inc.; Stryker Corporation; Alcon Laboratories, Inc.; Aspen Surgical Products, Inc.; Medtronic, Inc.; Ethicon, Inc.; and Becton, Dickinson and Company

Click Here For Access Full Report : https://goo.gl/6dnWM1

Biotechnology Services Outsourcing Market Is Expected To Reach USD 92.9 Billion By 2025

Pharmaceutical industry has been adaptive of the function of outsourcing certain clinical and corporate functions as early as 2002. Among the services outsourced, clinical trial management and contract manufacturing were the forerunners. For instance, Johnson & Johnson was the first pharmaceutical company to outsource its applications development and maintenance (ADM).

In 2015, over USD 50.0 billion was spent on pharmaceutical R&D activities majorly on oncology, diabetes, and autoimmune therapy classes, which is expected to propel the biotechnology services outsourcing market growth over the forecast period.

Shrinking profit margins coupled with rising competition in the market space, and augmenting regulatory burden are other vital impact rendering factors. The pharmaceutical services outsourcing market is expected to register growth at a CAGR of 8.7% during the forecast period. On the other hand, pending immigration legislations in the U.S. may hinder business economics and outsourcing risks.

Pharmaceutical and biotechnology industries in Europe are significantly investing in R&D in the recent year owing to rising demand for advanced medicines. This may be attributed to increasing aging population, incidence of chronic diseases, and communicable diseases.

View summary of this report, Click Here 

Further key findings from the study suggest:

• Consulting services are inclusive of regulatory compliance, remediation, and quality management systems consulting, which is expected to dominate the pharmaceutical services outsourcing market in 2025.
• In 2013, the U.S. FDA revised the guidelines for registration trials of drugs used in the treatment of acute bacterial skin and skin structure infections, thereby promoting growth of regulatory affairs services.
• Other services such as contract manufacturing, product upgrade, and IT consulting services are projected to grow swiftly. Increasing focus on generic medicine and regional expansions in developing regions are some of the key contributing factors
• Presence of cheap labor, skilled personnel and rapid growth of the pharmaceutical industry within the Asia Pacific region presents numerous opportunities for service providers, thereby representing a lucrative growth rate over the forecast period.
• Service based expertise may be found in players such QuintilesIMS, Parexel Corporation, Lachman Consultant Services, Inc., Concept Heidelberg GmbH, and others. These players compete on the basis of service quality, competitive pricing, and long-term relations with healthcare industry participants.

Click Here For Access Full Report : https://goo.gl/V2JBMX

Clinical laboratory tests market size is expected to reach USD 198.5 billion by 2024

Introduction of innovative solutions on the grounds of maximum efficiency and minimum error is expected to serve this market as a high impact-rendering driver.

Integrated workflow management systems, database management tools and patient test records are becoming increasingly important in the healthcare industry with companies processing as many as 100 to 150 billion samples per year.

Development and implementation of various informatics and data management solutions for performing seamless operations is expected to drive the growth of this market. Availability of technologically advanced products such as chemistry analyzers with high yield, low maintenance and, ease of usage has heightened the demand for early disease detection.

Increasing prevalence of chronic diseases and the consequent need to curb healthcare expenditure is also expected to drive market growth by increasing the demand for early and regular disease diagnosis. Moreover, presence of favorable reimbursement policies and availability of CLIA waived test is anticipated to increase base of target population.

View summary of this report, Click Here 

Further Key Findings From the Study Suggest:

• The basic metabolic panel segment dominated the clinical laboratory test market in 2015 mainly due to high acceptance rate of this panel of tests
• Liver panel is estimated to witness highest growth for liver cirrhosis testing owing to high rate of alcohol consumption
• Increasing demand for testing of blood lipid levels in cardiovascular and diabetes patients is anticipated to attribute towards significant growth of liver panel over the forecast period.
• Extensive support of manpower and established infrastructure are the main factors attributing to largest share of central laboratories
• North America is the most developed clinical laboratory tests market due to factors such as high awareness levels, rising prevalence of cardiovascular disorders, and high market penetration of technologically advanced diagnostic techniques
• Asia Pacific is anticipated to witness significant growth over 9% during the forecast period with presence of huge untapped opportunities, increasing base of target population, and positive economic growth.
• Some of the key companies are Quest Diagnostics, Millipore Sigma, LabCorp, and Genoptix Medical Laboratory
• Strategic initiatives implemented by key players to maintain market position include merger and acquisition of small players and development of cost effective clinical tests.

Click Here For Access Full Report : https://goo.gl/JC5tdy

Anxiety disorders and depression treatment market growth is expected to reach a value of USD 18.3 billion by 2025

The rising incidence of depression worldwide is anticipated to drive the market growth in the coming years. Increasing adoption of devices and psychotherapies has resulted in the declining demand for antidepressants in the recent years.

The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.

View summary of this report, Click Here 

Further key findings from the study suggest:

• Presently, the antidepressant drugs segment holds the largest revenue share. However, due to the rising occurrence of adverse events associated with these therapeutics, this segment’s growth is expected to wane
• Patent expiration of branded medicines and introduction of generic biosimilars, which are cost effective, are responsible for the shrinking market of antidepressants
• On the other hand, introduction of new medicines, such as Duloxetine, Fetzima, and Brintellix, are predicted to fuel the demand for therapeutics in the coming years 
• Furthermore, the personalized therapies and devices segment is expected to register the fastest growth owing to its growing adoption by healthcare professionals as they exert fewer side effects as compared to drugs
• Cognitive behavioral therapy held the majority share in 2015 and is expected to register substantial growth in the coming years owing to the shifting preference of healthcare professionals toward this segment
• Transcranial Magnetic Stimulation (TMS) is predicted to witness lucrative growth due to the introduction of technologically advanced devices such as MagVita TMS Therapy System by MagVenture in July 2015 and Brainsway Deep TMS in January 2013
• North American regional segment for anxiety disorders and depression treatment reached a saturation level owing to the availability of several medicines and the high prevalence of depressive disorders in this region
• Pfizer, Inc.; Eli Lilly and Company;GlaxoSmithKline plc; AstraZeneca; and H. Lundbeck A/S captured a sizable share in 2015 and accounted for more than 60% of the antidepressant drugs vertical
• The revenue captured by antidepressants is expected to decrease with generics dominating the market during the forecast period

Click Here For Access Full Report : https://goo.gl/tk9i9x

Pacemaker Market Size Is Expected To Reach USD 12.3 Billion By 2025

The heightening prevalence of cardiac conditions coupled with the availability of medical coverage is a key driving factor governing the growth of Pacemaker globally. In addition, technological enhancements in these devices are supporting the expansion of this vertical.

Increasing prevalence of Cardiovascular Diseases (CVDs) is a high-impact growth rendering driver for this market. A death estimate of 17.5 million stemming from CVDs was reported by the World Health Organization in 2012. Currently, the high occurrence of CVDs is one of the key concern areas, to address which, government organizations and market participants are channelizing funds and efforts to offer the best possible cure. This is anticipated to foster R&D initiatives and increase the influx of advanced products in this space.

Additionally, increasing awareness about cardiovascular disorders and their long-term impact is increasing the preference of patients for advanced treatment options. This is expected to bolster the usage rate of these products.

On the other hand, these devices are cost prohibitive with the cost of pacemaker ranging from USD 10,000 to USD 30,000. The high price is likely to restrain the growth of the pacemaker market.

View summary of this report, Click Here 

Further key findings from the study suggest: 

• Implantable pacemakers held a lucrative share in 2015 and are also likely to grow at a profitable rate over the forecast period
• North America owing to its planned healthcare network, greater per capita income, and increasing awareness levels about the adverse effects of a prolonged cardiac condition helped this regional segment retain a sturdy share in the global pacemaker market
• Economic development in countries, such as India and China, unmet needs of the huge population chunk, and supportive initiatives undertaken by the government to improve healthcare access is projected to present avenues for investment, thereby boosting the growth of the Asia Pacific region
• Some of the key players operating in this space are Medtronic, BIOTRONIK, Inc., Boston Scientific Corporation, St. Jude Medical, ZOLL Medical Corporation, MEDICO S.p.A., Vitatron, Pacetronix, and Cordis, Inc.

Click here for access full report : https://goo.gl/emxtJj